We have first conducted a mutant proteomic analysis for clinical tissue specimens of 36 lung adenocarcinoma patients who harbored distinct EGFR mutations, Ex21 L858R, Ex19del, and no L858R/Ex19del. This evidence concerns the gene EGFR and lung adenocarcinoma.